Oncotarget

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/14/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Infliximab versus intravenous pulse methylprednisolone treatment for immunoglobulin-resistant kawasaki disease: a systematic review and adjusted indirect comparison metaanalysis

Han Chan, Han Chan, Yuhao Wang, Yuhao Wang, Junli Yan, Junli Yan, Gaofu Zhang, Gaofu Zhang, Mo Wang, Mo Wang, Haiping Yang _, Haiping Yang, Qiu Li and Qiu Li _

 

Han Chan1,2,*,Yuhao Wang1,*, Junli Yan1,2,*, Gaofu Zhang1,2, Mo Wang1,2, Haiping Yang1,2 and Qiu Li1,2

1 Department of Nephrology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

2 Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China

* These authors have contributed equally to this work

Correspondence to:

Haiping Yang, email: [email protected]

Qiu Li, email: [email protected]

Keywords: infliximab; methylprednisolone; intravenous immunoglobulin; mucocutaneous lymph node syndrome

Received: September 01, 2017    Accepted: November 16, 2017    Epub: December 14, 2017    


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23245